Bleakley Financial Group
MAIA icon

Bleakley Financial Group’s MAIA Biotechnology MAIA Stock Holding History

Bleakley Financial Group’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$214K Hold
181,623
– – ﹤0.01% 1094
2026
Q2 		$262K Buy
+181,623
New +$241K ﹤0.01% 900

Other funds holding MAIA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Centric Wealth Management
Centric Wealth Management Chicago, Illinois $657M AUM 18.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bleichroeder LP
Bleichroeder LP New York $1.02B AUM 33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Bleakley Financial Group's MAIA Position: Q3 2026 in Review

Bleakley Financial Group held its MAIA Biotechnology (MAIA) position steady in Q3 2026 at 181,623 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Bleakley Financial Group first reported a position in MAIA in Q2 2026 and has held it in 2 quarters since. The position peaked at $262K in Q2 2026. 31 funds tracked by Wall St. Rank hold MAIA as of Q3 2026.

  • Bleakley Financial Group held 181,623 shares of MAIA Biotechnology worth $214K as of Q3 2026.
  • Bleakley Financial Group left its MAIA Biotechnology share count unchanged in Q3 2026.
  • MAIA Biotechnology made up ﹤0.01% of Bleakley Financial Group's portfolio in Q3 2026, its #1094 holding.
  • Bleakley Financial Group first reported a position in MAIA Biotechnology in Q2 2026 and has held it in 2 quarters since.
  • Bleakley Financial Group's MAIA Biotechnology position peaked at $262K in Q2 2026.
  • 31 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q3 2026.

Based on Bleakley Financial Group's 13F filing for Q3 2026, filed 13 Nov 2026.